Vytorin, a cholesterol-lowering medicine from Merck & Co. and Schering-Plough Corp., did not benefit patients with a grave heart-valve condition and seemed to raise their cancer risk, according to clinical-trial data presented Monday. Critics said the study highlights concerns about the drug's safety and efficacy. It is "too early to estimate the potential impact" of the trial in long-term guidance, Merck CEO Richard Clark said.

Related Summaries